Phoqus announces that it has signed a feasibility agreement with Unilever and also provides a trading update prior to entering the Company's close period.

Phoqus announces that its in-house development programme in collaboration with Diurnal Limited ("Diurnal"), a subsidiary of Biofusion plc, has begun its Phase I clinical trials programme on Chronocort - the first Circadian endocrine treatment for adrenal insufficiency.

Phoqus announces that it has published its Admission Document relating to the Company's £10 million fundraising (the "Placing") and to the admission of all of the Company's Ordinary Shares to trading on AIM ("Admission"), which is expected to take place at 08:00 on Thursday 3 November 2005 under the ticker symbol PQS.

Phoqus Group Limited ("Phoqus" or "the Company"), an oral drug delivery and development company, announces its intention to seek a listing on the AIM market of the London Stock Exchange via an institutional placing.

Following a successful audit by the Medicines and Healthcare products Regulatory Agency (MHRA), Phoqus has received its Manufacturer's Authorization for Investigational Medicinal Products (IMPs).